IRIS
BARCHIESI, Francesco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.185
EU - Europa 3.036
AS - Asia 1.166
AF - Africa 66
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 1
SA - Sud America 1
Totale 10.462
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.166
UA - Ucraina 769
IE - Irlanda 457
TR - Turchia 429
IT - Italia 381
SE - Svezia 369
SG - Singapore 327
DE - Germania 325
DK - Danimarca 283
CN - Cina 202
FI - Finlandia 164
KR - Corea 152
GB - Regno Unito 137
FR - Francia 115
CI - Costa d'Avorio 62
IN - India 24
IR - Iran 23
CA - Canada 17
BE - Belgio 14
BA - Bosnia-Erzegovina 6
EU - Europa 6
HK - Hong Kong 4
MA - Marocco 4
ID - Indonesia 2
MX - Messico 2
NL - Olanda 2
PL - Polonia 2
A1 - Anonimo 1
AL - Albania 1
AT - Austria 1
AU - Australia 1
BG - Bulgaria 1
CH - Svizzera 1
CL - Cile 1
CZ - Repubblica Ceca 1
ES - Italia 1
IL - Israele 1
JP - Giappone 1
KG - Kirghizistan 1
LT - Lituania 1
MD - Moldavia 1
PT - Portogallo 1
RO - Romania 1
RS - Serbia 1
RU - Federazione Russa 1
Totale 10.462
Salva come PNG Salva come JPEG
Città #
Jacksonville 794
Fairfield 742
Chandler 537
Dublin 452
Boardman 423
Ashburn 356
Wilmington 313
Woodbridge 303
Seattle 252
Houston 245
Des Moines 242
Cambridge 241
New York 208
Ann Arbor 193
Lawrence 173
Princeton 173
San Mateo 172
Singapore 122
Turin 103
San Diego 97
Abidjan 62
Centro 51
Redmond 41
Beijing 32
London 24
Shanghai 23
Helsinki 18
Norwalk 18
Washington 18
Los Angeles 17
Marche 16
Ottawa 15
Brussels 14
Guangzhou 13
Kilburn 13
Pune 12
Wuhan 12
Ancona 11
Dallas 10
Bologna 9
Izmir 8
Milan 8
Bari 7
San Severino Marche 7
Falls Church 6
Ferrara 6
Sarajevo 6
Andover 5
Jiaxing 5
Jinhua 5
Prescot 5
Acton 4
Auburn Hills 4
Chiswick 4
Falconara Marittima 4
Hanover 4
Paris 4
Pesaro 4
Rome 4
Seoul 4
Shenzhen 4
Wuxi 4
Appignano 3
Cingoli 3
Delhi 3
Heze 3
Hounslow 3
Islington 3
Macerata 3
Mountain View 3
Nanjing 3
Porto 3
Squinzano 3
Yiwu 3
Amsterdam 2
Arco 2
Bhopal 2
Cava De' Tirreni 2
Central 2
Conegliano 2
Copenhagen 2
Corridonia 2
Fayetteville 2
Indore 2
Monterrey 2
Montesilvano Marina 2
Munich 2
Naples 2
Napoli 2
New Bedfont 2
Olgiate Comasco 2
Osimo 2
Palermo 2
Quanzhou 2
Rimini 2
Santa Clara 2
Tiantai Chengguanzhen 2
Tolentino 2
Vallefoglia 2
Villafranca Padovana 2
Totale 6.770
Salva come PNG Salva come JPEG
Nome #
Antimicrobial Resistance: A Challenge for the Future 160
Invasive Aspergillosis in liver transplant recipients: Epidemiology, clinical characteristics, treatment, and outcomes in 116 cases 113
Candida guilliermondii fungemia in patients with hematologic malignancies. 110
Trichosporon beigelii fungaemia in an AIDS patient. 106
Delay of antifungal therapy influences the outcome of invasive aspergillosis in experimental models of infection 105
Epidemiology, clinical characteristics, and outcome of candidemia in a tertiary referral center in Italy from 2010 to 2014 103
Activity of nitazoxanide alone and in combination with azithromycin and rifabutin against Cryptosporidium parvum in cell culture. 100
Epidemiology and outcome of systemic infections due to saprochaete capitata: case report and review of the literature 98
Antimicrobial activity of polycationic peptides 96
Anidulafungin in combination with amphotericin B against Aspergillus fumigatus. 93
Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU 93
In-vitro activity of the synthetic protegrin IB-367 alone and in combination with antifungal agents against clinical isolates of Candida spp. 92
Comparison of three methods for testing azole susceptibilities of Candida albicans strains isolated sequentially from the oral cavities of aids patients. 91
Changing characteristics and risk factors of patients with and without incident HCV infection among HIV-infected individuals 91
Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole. 90
Sequential therapy with caspofungin and fluconazole for Candida albicans infection. 90
In-vitro effect of short-term exposure to two synthetic peptides, alone or in combination with clarithromycin or rifabutin, on Cryptosporidium parvum infectivity. 90
Activity of buforin II alone and in combination with azithromycin and minocycline against Cryptosporidium parvum in cell culture. 89
Multicentre validation of a EUCAST method for the antifungal susceptibility testing of microconidia-forming dermatophytes 89
Effects of caspofungin against Candida guilliermondii and Candida parapsilosis. 88
Species distribution and antifungal susceptibilities of bloodstream Candida isolates: a nine-years single center survey 87
High rate of ceftobiprole resistance among clinical methicillin-resistant Staphylococcus aureus isolates from a hospital in central Italy 85
Epidemiology and microbiology of surgical wound infections. 83
Comparison of liver fibrosis progression in HIV/HCV co-infected and HCV mono-infected patients by transient elastometry 83
Comparison of visual 24-hour and spectrophotometric 48-hour MICs to CLSI reference microdilution MICs of fluconazole, itraconazole, posaconazole, and voriconazole for Candida spp.: a collaborative study. 82
Analysis of antibody response to Cryptococcus neoformans in five patients with AIDS and cryptococcosis by immunoblotting. 82
Carbapenem-Resistant Klebsiella pneumoniae influences the outcome of early infections in liver transplant recipients 82
In vitro activities of voriconazole in combination with other three antifungal agents against Candida glabrata 81
ACTIVITY OF THE NEW ANTIFUNGAL TRIAZOLE, POSACONAZOLE, AGAINST CRYPTOCOCCUS NEOFORMANS 81
In-vitro activity of rifabutin and albendazolo singly and in combination with other clinically used antimicrobial agents against Pneumocystis carinii. 80
Characterisation of candidemia in patients with recent surgery: A 7-year experience 80
In-vitro activity of five antifungal agents against uncommon clinical isolates of Candida spp. 79
Prevalence and predictors of malignancies in a polycentric cohort of HIV patients from Italy 79
In vitro activity of the synthetic lipopeptide PAL-Lys-Lys-NH(2) alone and in combination with antifungal agents against clinical isolates of Cryptococcus neoformans. 78
Evaluation of the disk diffusion method compared to the microdilution method in susceptibility testing of anidulafungin against filamentous fungi. 77
Comparative Effects of Micafungin, Caspofungin, and Anidulafungin against a Difficult-To-Treat Fungal Opportunistic Pathogen, Candida glabrata 77
Candidemia in the elderly: What does it change? 77
Reply to Ma et al.: Osteomyelitis caused by aspergillus species 77
An (Italian) proposal for a comprehensive approach to infections across the surgical pathway 76
Clinical and epidemiological characteristics of KPC-producing Klebsiella pneumoniae from bloodstream infections in a tertiary referral center in Italy 73
Factors related to outcome of bloodstream infections due to Candida parapsilosis complex 72
Epidemiology of onychomycosis and paronychia in the area of ANCONA (ITALY) over a period of 5 years 71
Osteomyelitis caused by Aspergillusspecies: a review of 310 reported cases 70
Evaluating Liver Fibrosis by Transient Elastometry in Patients With HIV-HCV Coinfection and Monoinfection. 70
Infection due to Absidia corymbifera in a patient with a massive crush trauma of the foot 69
Aspergillus spp invasive external otitis: favourable outcome with a medical approach 69
In vitro activity of the lipopeptide derivative (Pal-Lys-Lys-NH), alone and in combination with antifungal agents, against clinical isolates of dermatophytes. 68
In-vitro activity of polycationic peptides against Cryptosporidium parvum, Pneumocystis carinii and yeast clinical isolates. 68
In vitro activity of the protegrin IB-367 alone and in combination compared with conventional antifungal agents against dermatophytes 68
In vitro susceptibility of dermatophytes to conventional and alternative antifungal agents. 68
Statistical analyses of correlation between fluconazole MICs for Candida spp. assessed by standard methods set forth by the European Committee on Antimicrobial Susceptibility Testing (E.Dis. 7.1) and CLSI (M27-A2). 67
ELECTROPHORETIC KARYOTYPING AND TRIAZOLE SUSCEPTIBILITY OF CANDIDA GLABRATA CLINICAL ISOLATES 66
In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens 66
Effects of amphotericin B on Aspergillus flavus clinical isolates with variable susceptibilities to the polyene in an experimental model of systemic aspergillosis. 66
null 66
Turbidimetric and visual criteria for determining the in vitro activity of six antifungal agents against Candida spp. and Cryptococcus neoformans. 65
Experimental induction of fluconazole resistance in Candida tropicalis ATCC 750. 64
In vitro and in vivo activities of posaconazole against zygomycetes with various degrees of susceptibility. 64
In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans. 63
Heterozygosis and pathogenicity of Cryptococcus neoformans AD-hybrid isolates. 63
EUCAST Technical Note on voriconazole. 63
Interactions of Posaconazole and Flucytosine against Cryptococcus neoformans. Antimicrob. Agents Chemother. 63
Anticryptosporidial activity of ranalexin, lasalocid and azithromycin alone and in combination in cell lines. 63
Acute histoplasmosis in immunocompetent travelers: a systematic review of literature 63
How to: EUCAST recommendations on the screening procedure E.Def 10.1 for the detection of azole resistance in Aspergillus fumigatus isolates using four-well azole-containing agar plates 63
In vitro activities of terbinafine in combination with fluconazole and itraconazole against isolates of Candida albicans with reduced susceptibility to azoles. 62
Central venous catheter unrelated candidemia influences the outcome of infection in patients with solid tumors 62
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial 61
In vitro activities of membrane-active peptides alone and in combination with clinically used antimicrobial agents against Stenotrophomonas maltophilia. 60
Interactions of posaconazole and flucytosine against Cryptococcus neoformans. 60
EUCAST technical note on posaconazole. 60
Antifungal susceptibility patterns of yeast isolates causing bloodstream infections. 60
Sustained increase of serum creatine phosphokinase levels and progressive muscle abnormalities associated with raltegravir use during 32-week follow-up in an HIV-1 experienced patient on simplified HAART regimen, intolerant to protease inhibitors and abacavir: a case report. 60
Clinical efficacy and tolerability of caspofungin in a renal transplant patient with Aspergillus flavus lung infection: case report. 60
In vitro activities of voriconazole in combination with three other antifungal agents against Candida glabrata. 59
Caspofungin in combination with amphotericin B against Candida glabrata. 59
Disruption of homocitrate synthase genes in Candida albicans affects growth but not virulence. 59
Ceftazidime-Avibactam for the Treatment of Multidrug-Resistant Pathogens: A Retrospective, Single Center Study 59
Comparison of four methods for DNA typing of clinical isolates of Candida glabrata. 58
Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital. 58
Caspofungin in combination with amphotericin B against Candida parapsilosis. 58
Posaconazole and amphotericin B combination therapy against Cryptococcus neoformans infection. 58
Candidemia in intensive care units over nine years at a large Italian university hospital: Comparison with other wards 58
Posaconazole prophylaxis in experimental systemic zygomycosis. 57
Comparison between disk diffusion and microdilution methods for determining susceptibility of clinical fungal isolates to caspofungin. 57
In vitro activity of Tachyplesin III alone and in combination with terbinafine against clinical isolates of dermatophytes. 57
Anticryptosporidial activity of cationic peptides alone and in combination with inhibitors of ion transport systems. 57
Bloodstream infections in the COVID-19 era: results from an Italian multi-centre study 57
In vitro and in vivo effects of echinocandins against Candida parapsilosis sensu stricto, Candida orthopsilosis and Candida metapsilosis. 56
Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B. 56
EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. 56
SIMIFF study: Italian fungal registry of mold infections in hematological and non-hematological patients. 56
Electrophoretic karyotyping and antifungal susceptibility patterns of Candida parapsilosis clinical isolates causing deep and superficial fungal infections 56
Development and validation of a prediction model for severe respiratory failure in hospitalized patients with SARS-CoV-2 infection: a multicentre cohort study (PREDI-CO study) 56
Treatment of murine cryptococcal meningitis with UR-9751 and UR-9746. 55
EUCAST technical note on fluconazole. 55
EUCAST technical note on Amphotericin B 55
International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole. 55
Molecular epidemiology of Italian clinical Cryptococcus neoformans var. grubii isolates 55
Inhibition of growth of Pneumocystis carinii by lactoferrins singly and in combination with pyrimethamine, clarithromycin and minocycline. 54
Totale 7.265
Salva come PNG Salva come JPEG
Categoria #
all - tutte 63.780
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 63.780
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020873 0 0 0 0 162 9 170 8 170 81 34 239
2020/20212.631 148 273 353 48 304 190 253 159 223 283 289 108
2021/20221.519 133 433 13 42 20 63 117 70 76 136 156 260
2022/20232.071 215 172 150 113 135 354 13 96 563 11 176 73
2023/20241.299 214 25 68 240 248 280 26 18 15 15 15 135
2024/2025670 225 208 166 30 41 0 0 0 0 0 0 0
Totale 10.658